AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Sign up Log in

Episurf Share Issue/Capital Change 2016

May 31, 2016

3157_rns_2016-05-31_508ca910-7a4b-4996-819f-fc14ac3a3905.pdf

Share Issue/Capital Change

Open in viewer

Opens in your device viewer

{# SEO P0-1: filing HTML is rendered server-side so Googlebot sees the full text without executing JS or following an iframe to a Disallow'd CDN path. The content has already been sanitized through filings.seo.sanitize_filing_html. #}

Company Announcement May 31, 2016

Change in shares and number of votes in Episurf Medical AB

On the behalf of shareholders in Episurf Medical AB, conversions of class A shares to B shares were carried out during May in accordance with the Articles of Association. Through the conversion, the number of A shares have decreased by 5 747 and the number of B shares have increased by the same amount. The total number of shares amounts to 15 963 305, of which 3 431 974 are A shares and 12 531 331 are B shares. The total number of votes after the conversations amounts to 22 827 253.

For more information, please contact:

Pål Ryfors, CFO, Episurf Medical Tel: +46 709 62 36 69 Email: [email protected]

About Episurf Medical

Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and personalized treatment alternatives. Episurf Medical's Episealer® personalized implants and Epiguide® surgical drill guides are developed for treating localized cartilage injury in joints. Episurf Medical's μiFidelity® system enables implants to be cost-efficiently tailored to each individual's unique injury for the optimal fit and minimal intervention.

Episurf Medical's head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company's website: www.episurf.com. The information in this press release is such that Episurf Medical AB is required to disclose in accordance with the Securities Markets Act and/or the Financial Instruments Trading Act.